Sharareh Eskandari

Dr. Sharareh Eskandari

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
Sharareh EskandariSharareh Eskandari
Sharareh Eskandari
TGThalia Guerin
Thalia Guerin
Istvan TothIstvan Toth
Istvan Toth
Rachel StephensonRachel Stephenson
Rachel Stephenson
Self-assembled peptides have shown outstanding characteristics for vaccine delivery and drug targeting. Peptide molecules can be rationally designed to self-assemble into specific nanoarchitectures in response to changes in their assembly environment including: pH, temperature, ionic strength, and interactions between host (drug) and guest molecules. The resulting supramolecular nanostructures include nanovesicles, nanofibers, nanotubes, nanoribbons, and hydrogels and have a diverse range of mechanical and physicochemical properties. These molecules can be designed for cell-specific targeting by including adhesion ligands, receptor recognition ligands, or peptide-based antigens in their design, often in a multivalent display. Depending on their design, self-assembled peptide nanostructures have advantages in biocompatibility, stability against enzymatic degradation, encapsulation of hydrophobic drugs, sustained drug release, shear-thinning viscoelastic properties, and/or adjuvanting properties. These molecules can also act as intracellular transporters and respond to changes in the physiological environment. Furthermore, this class of materials has shown sequence- and structure-dependent impacts on the immune system that can be tailored to non-immunogenic for drug targeting, and immunogenic for vaccine delivery. This review explores self-assembled peptide nanostructures (beta sheets, alpha helices, peptide amphiphiles, amino acid pairing, elastin like polypeptides, cyclic peptides, short peptides, Fmoc peptides, and peptide hydrogels) and their application in vaccine delivery and drug targeting.

1 May 2012 in Carbohydrate Polymers
Verified
Journal Article
Closed access
JVJaleh Varshosaz
Jaleh Varshosaz
Sharareh EskandariSharareh Eskandari
Sharareh Eskandari
MTMajid Tabbakhian
Majid Tabbakhian

20 January 2010 in Pharmaceutical Development and Technology
Verified
Journal Article
Closed access
PDF file
JVJaleh Varshosaz
Jaleh Varshosaz
Sharareh EskandariSharareh Eskandari
Sharareh Eskandari
MTMajid Tabakhian
Majid Tabakhian
The objective of this study was production of nanostructured lipid carriers (NLC) of valproic acid for brain delivery thought the nasal pathway. NLC were prepared by solvent diffusion method using a Taguchi design. The lipid, oil and valproic acid were dissolved in organic phase then dispersed in aqueous phase containing the surfactant. The most effective factors on size were surfactant concentration, organic/aqueous phase ratio and acetone/ethanol volume ratio. Zeta potential was more affected by the lipid type, while the surfactant concentration and sonication time were more effective variables on drug release rate. The entrapment efficiency was more affected by lipid/drug weight ratio. Optimum formulation obtained with 400 mg lipid, 400 mg valproic acid, 2% surfactant, 1:5 organic/aqueous phase ratio, 1:1 acetone/ethanol volume ratio and 2 min sonication.

1 February 2011 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JVJaleh Varshosaz
Jaleh Varshosaz
Sharareh EskandariSharareh Eskandari
Sharareh Eskandari
MMMohsen Minaiyan
Mohsen Minaiyan
MTMajid Tabbakhian
Majid Tabbakhian
The treatment of brain disorders is one of the greatest challenges in drug delivery because of a variety of main barriers in effective drug transport and maintaining therapeutic concentrations in the brain for a prolonged period. The objective of this study was delivery of valproic acid (VPA) to the brain by intranasal route. For this purpose, nanostructured lipid carriers (NLCs) were prepared by solvent diffusion method followed by ultrasonication and characterized for size, zeta potential, drug-loading percentage, and release. Six groups of rats each containing six animals received drug-loaded NLCs intraperitoneally (IP) or intranasally. Brain responses were then examined by using maximal electroshock (MES). The hind limb tonic extension:flexion inhibition ratio was measured at 15-, 30-, 60-, 90-, and 120-minute intervals. The drug concentration was also measured in plasma and brain at the most protective point using gas chromatography method. The particle size of NLCs was 154 ± 16 nm with drug-loading percentage of 47% ± 0.8% and drug release of 75% ± 1.9% after 21 days. In vivo results showed that there was a significant difference between protective effects of NLCs of VPA and control group 15, 30, 60, and 90 minutes after treatment via intranasal route (P < 0.05). Similar protective effect was observed in rats treated with NLCs of VPA in intranasal route and positive control in IP route (P > 0.05). Results of drug determination in brain and plasma showed that brain:plasma concentration ratio was much higher after intranasal administration of NLCs of VPA than the positive control group (IP route). In conclusion, intranasal administration of NLCs of VPA provided a better protection against MES seizure.

23 February 2021 in mBio
Verified
Journal Article
Open access
PDF file
VOVictoria Ozberk
Victoria Ozberk
SRSimone Reynolds
Simone Reynolds
YHYongbao Huo
Yongbao Huo
ACAinslie Calcutt
Ainslie Calcutt
Sharareh EskandariSharareh Eskandari
Sharareh Eskandari
MGMichael F. Good
Michael F. Good
Infections with Streptococcus pyogenes and their sequelae are responsible for an estimated 18 million cases of serious disease with >700 million new primary cases and 500,000 deaths per year. Despite the burden of disease, there is currently no vaccine available for this organism. Here, we define a combination vaccine P*17/K4S2 comprising of 20-mer B-cell peptide epitopes, p*17 (a mutant derived from the highly conserved C3-repeat region of the M-protein), and K4S2 (derived from the streptococcal anti-neutrophil factor, Spy-CEP). The peptides are chemically conjugated to either diphtheria toxoid (DT) or a nontoxic mutant form of diphtheria toxin, CRM197. We demonstrate that a prime-pull immunization regimen involving two intramuscular inoculations with P*17/K4S2 adjuvanted with a two-component liposomal adjuvant system (CAF01; developed by Statens Serum Institut [SSI], Denmark), followed by an intranasal inoculation of unadjuvanted vaccine (in Tris) induces peptide- and S. pyogenes-binding antibodies and protects from mucosal and skin infection with hypervirulent covR/S mutant organisms. Prior vaccination with DT does not diminish the response to the conjugate peptide vaccines. Detailed Good Laboratory Practice (GLP) toxicological evaluation in male and female rats did not reveal any gross or histopathological adverse effects. IMPORTANCE A vaccine to control S. pyogenes infection is desperately warranted. S. pyogenes colonizes the upper respiratory tract (URT) and skin, from where it can progress to invasive and immune-mediated diseases. Global mortality estimates for S. pyogenes-associated diseases exceeds 500,000 deaths per year. S. pyogenes utilizes antigenic variation as a defense mechanism to circumvent host immune responses and thus a successful vaccine needs to provide strain-transcending and multicompartment (mucosal and skin) immunity. By defining highly conserved and protective epitopes from two critical virulence factors (M-protein and Spy-CEP) and combining them with a potent immunostimulant, CAF®01, we are addressing an unmet clinical need for a mucosally and skin-active subunit vaccine. We demonstrate that prime-pull immunization (2× intramuscular injections followed by intranasal immunization) promotes high sustained antibody levels in the airway mucosa and serum and protects against URT and invasive disease.

1 July 2016 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ACAmy Chan
Amy Chan
Waleed HusseinWaleed Hussein
Waleed Hussein
KGKhairunnisa Abdul Ghaffar
Khairunnisa Abdul Ghaffar
Nirmal MarasiniNirmal Marasini
Nirmal Marasini
AMAhmed Mostafa
Ahmed Mostafa
Istvan TothIstvan Toth
Istvan Toth